Full Press Release Details
Medical Shares Results from Its Pivotal Clinical Trial, Achieving 100% Robotic Navigation Success for the LIBERTY
Endovascular Robotic System
robotic navigation was achieved in every case and
the primary endpoint of the study
showed a 92% reduction in radiation exposure with no adverse events reported
Mass., April 9, 2025 - Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY Endovascular
Robotic System, presented for the first time the data from its ACCESS-PVI pivotal trial at the Society of Interventional Radiology (SIR)
annual meeting. The study was performed at three leading medical centers in the U.S.; Memorial Sloan Kettering Cancer Center (New York,
NY), Baptist Hospital of Miami (Miami, FL) and Brigham and Women's Hospital (Boston, MA). The late-breaking podium presentation
was given by Francois Cornelis, M.D., PhD, Director of the Neuro Vascular Interventional Radiology Program at Memorial Sloan Kettering
data presented concluded that robotic endovascular procedures using LIBERTY are feasible and significantly minimize radiation
Highlights of the ACCESS-PVI Study:
ACCESS-PVI data and the performance of the system throughout the study reflect the hard work that the team has put into LIBERTY
over the past few years," commented Harel Gadot, Chairman, CEO and President. "We are extremely pleased with the results
in all aspects. As we shift focus to building our commercial capabilities and preparing for launch, we are confident that LIBERTY
will be well received in the market."
are very satisfied with the clinical data, as well as with the investigators' feedback in terms of the short learning curve and
intuitive operation of the device," commented Dr. Juan Diaz-Cartelle, the Company's Chief Medical Officer. "We are
looking forward to working with interventional physicians and staff upon FDA's clearance."
is an investigational device pending FDA 510(k) clearance, and is currently not available for sale in the U.S.
Medical Inc. (NASDAQ: MBOT) is a pre-commercial stage medical technology company with a vision to redefine endovascular robotics and
improve the quality of care for millions of patients and providers globally. The Company has developed the world's first single-use,
fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems.
information about Microbot Medical is available at http://www.microbotmedical.com.
to future financial and/or operating results, future growth in research, technology, clinical development, commercialization and potential
opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals,
plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements
that contain words such as "will," "believes," "plans," "anticipates," "expects"
and "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, the Company's need for and ability to obtain additional working capital to continue
its transition to a commercially focused company, market conditions, risks inherent in the development and/or commercialization of the
LIBERTY Endovascular Robotic System, uncertainty in the results of regulatory pathways and regulatory approvals, including
whether the FDA will timely grant 510(k) clearance to commercially market the LIBERTY Endovascular Robotic System in
the United States if at all, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel
or processes or procedures at the FDA and the recent announcement of tariffs on imports into the U.S., disruptions resulting from new
and ongoing hostilities between Israel and the Palestinians and other neighboring countries, and maintenance of intellectual property
rights. Additional information on risks facing Microbot Medical can be found under the heading "Risk Factors"
in Microbot Medical's periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC's
web site at www.sec.gov. Microbot Medical disclaims any intent or obligation to update these forward-looking statements,
except as required by law.
Contact: IR@microbotmedical.com